Endonovo Therapeutics Announces Issuance of U.S. Patent on Production of Human 
Key Patent Covers Production of Human Proteins Used as Biologics,
including EPO, G-CSF, GM-CSF, and IL-2
LOS ANGELES, CA -- (Marketwired) -- 08/09/16 --  Endonovo
Therapeutics, Inc. (OTCQB: ENDV), a developer of bioelectronic
devices and non-invasive Electroceuticals for the treatment of
inflammatory conditions in vital organs, announced today that the
U.S. Patent and Trademark Office issued U.S. Patent No. 9,410,143
covering the use of electromagnetic stimulation of cells to produce
biological molecules. This newly-issued patent covers the production
of human biomolecules commonly used as biologics, including EPO,
G-CSF, GM-CSF, and IL-2.
The system and process protected by the patent covers the production
of therapeutic proteins by stimulating adult stem cells using the
Company's proprietary Time-Varying Electromagnetic Field (TVEMF)
technology in a proprietary three dimensional bioreactor system. The
technology is part of Endonovo's Cytotronics(TM) platform, which
harnesses the bulk electrical properties of tissues and cells, namely
magnetically-induced electrical field pathways to expand and enhance
the therapeutic properties of cell therapies and to produce human
Biopharmaceuticals, also known as biologics, are pharmaceutical drug
products manufactured in, extracted from, or semi-synthesized from
biological sources. These drugs differ from traditional chemically
synthesized drugs and include vaccines, hormones, blood components,
recombinant therapeutic proteins and living cells used in cell
therapies. Biologics are commonly used to stimulate the growth of
specific blood cell types, such as red and white blood cells, and to
mobilize blood stem cells from the bone marrow into the bloodstream
allowing for their collection and subsequent transplantation into
patients following chemotherapy.
Generating sales of approximately US$6 billion in 2014, and with
recent and upcoming patent expirations on a number of biologics by
the year 2020, first and next-generation G-CSF products commonly used
in the treatment of chemotherapy-induced neutropenia, represent an
attractive market for biosimilar and biosuperior proteins, according
to Competitor Analysis Series. The market for biosimilar G-CSF is
forecasted to grow at a CAGR of 20.2% from 2014 to 2019, reaching a
value of $1.1 billion in 2019, according to BCC Research.
Alan Collier, Chief Executive Officer of Endonovo, commented, "The
patent issued today represents significant and important protection
to our Cytotronics platform allowing us to move forward with the
platform's development of while addressing many of the current
drawbacks of culturing cells outside of the body to create better
cell therapies and biologics."
Mr. Collier went on to say, "Although follow-on biologics represent a
lucrative opportunity for some biotechs by potentially costing 20-30
percent less than their brand name counterparts, we are looking at
creating next-generation biosuperior proteins that are created using
human cells rather than using recombinant-DNA technology in E.coli
and yeast systems."
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a leading developer of
bioelectronic-applications in cell therapies and non-invasive
Electroceuticals(TM). Endonovo's Immunotronics(TM) platform is
dedicated to treating patients with life-threatening inflammatory
conditions, such as acute liver injury and fulminant hepatic failure,
using proprietary non-invasive Electroceutical(TM) devices. The
Company's non-invasive platform is based on magnetically-induced
electrical field pathways that target inflammation and cell death.
The Company's Cytotronics(TM) platform harnesses the bulk electrical
properties of cells and tissues, namely magnetically-induced
electrical field pathways to expand and enhance the therapeutic
potential of cell therapies and produce next-generation biologics.
Safe Harbor Statement
This press release contains information that constitutes
forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
All statements, trends, analysis, and other information contained in
this press release including words such as "anticipate," "believe,"
"plan," "estimate," "expect," "intend," and other similar expressions
of opinion, constitute forward-looking statements. Any such
forward-looking statements involve risks and uncertainties that could
cause actual results to differ materially from any future results
described within the forward-looking statements. Risk factors that
could contribute to such differences include those matters more fully
disclosed in the Company's reports filed with the Securities and
Exchange Commission. The forward-looking information provided herein
represents the Company's estimates as of the date of the press
release, and subsequent events and developments may cause the
Company's estimates to change. The Company specifically disclaims any
obligation to update the forward-looking information in the future.
Therefore, this forward-looking information should not be relied upon
as representing the Company's estimates of its future financial
performance as of any date subsequent to the date of this press
Investors: Sign Up for Email Alerts on Endonovo
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=3042762
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Steven Barnes
Senior Vice President of Investor Relations
(800) 701-1223, Ext. 108